… of no anticoagulation prior to diagnosis of COVID-19 was … 541 adult patients with COVID-19
and 28 200 (30·8%) deaths. Our … This may be less so for oral anticoagulants than for heparin. …

… autopsies performed in COVID-19 deaths revealed bilateral … coagulation markers in COVID-19,
heparins are being studied … in-hospital mortality 25.6% Compared to no anticoagulation, …

… primary anticoagulant in the pAC group was enoxaparin (… the benefit of heparin and
non-heparin anticoagulants or to … between anticoagulant treatment and decreased mortality in …

… use of therapeutic anticoagulation in patients hospitalized with COVID-19, especially heparin,
which … anticoagulation has no effect on short-term mortality among hospitalized adults with …

… and mortality of severe COVID-19, the role of anticoagulation … heparin (LMWH) or subcutaneous
unfractionated heparin (UFH) … ) or direct oral anticoagulants (DOACs) (apixaban, one …

… anticoagulation with therapeutic enoxaparin or heparin drip had approximately half the
mortality rate of those receiving the basic thromboprophylaxis regimen (26% vs 61% mortality …

… and anticoagulants in patients hospitalized with COVID-19, … that heparin has beneficial
effects in preventing COVID-19-… outpatients with COVID-19, aspirin or apixaban did not …

… heparins such as enoxaparin predominantly inhibit factor Xa but also inhibit thrombin to some
degree. Orally active, specific factor Xa inhibitors such as apixaban … ongoing anticoagulant …

… intensity: enoxaparin ≤40 mg once daily, enoxaparin 40 mg … heparin 5000 units or less 2
or 3 times a day, apixaban 2.5 mg … In‐hospital mortality was higher in the COVID‐19 group …

… (AC) and antiplatelet (AP) agents in the management of COVID-19. We aim to … COVID-19
and the thrombosis associated with it while also evaluating its effect on the COVID-19 mortality …